期刊文献+

老年患者鲍氏不动杆菌感染的分布及耐药性 被引量:8

Distribution and Antimicrobial Resistance of Acinetobacter baumannii Infection in Elderly Patients
下载PDF
导出
摘要 目的 探讨老年患者鲍氏不动杆菌感染的分布特征及耐药性。方法 对我院2001年6月~2005年4月老年患者感染的鲍氏不动杆菌分布部位、患者基础疾病及其对15种抗菌药物的药敏结果进行分析。结果 检出184株鲍氏不动杆菌,标本来源为痰液、尿液、咽拭子、脓液等;对第三代头孢菌素和环丙沙星、氧氟沙星的耐药率均>50.0%;耐药率最低的药物是亚胺培南,为2.2%,其次为阿米卡星(37.5%)和氨苄西林/舒巴坦(39.7%),耐药率最高的药物是氨苄西林,为83.2%。结论 老年患者感染的鲍氏不动杆菌耐药率较高,宜根据药敏试验结果合理选择抗菌药物。 OBJECTIVE To investigate the distribution and antimicrobial resistance of Acinetobacter baumannii infection in the elderly patients in our hospital. METHODS One hundred and eighty-four strains of A. baumannii isolated from elderly patients with infection from Jun 2001 to Apr 2005 were collected and antimicrobial susceptibility test was performed. RESULTS All strains of A. baurnannii were from sputum, urine, pus, etcl the resistance of the strains to the third generation cephalosporin, ciprofloxacin and ofloxacin was all more than 50.0% the resistance rate to imipenem was the lowest(2.2%), followed by amikacin(37. 5 %)and ampicillin/ sulbactam (39. 7%), and the resistant rate to ampicillin was the highest (83.2%). CONCLUSIONS The antimicrobial resistance of A. baumannii in the elderly patients is high, the antibiotic treatment must depend on antimicrobial susceptibility test.
机构地区 上海市天平医院
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2006年第9期1067-1068,共2页 Chinese Journal of Nosocomiology
关键词 老年患者 鲍氏不动杆菌 药敏试验 Elderly patient Acinetobacter baumannii Antimicrobial susceptibility test
  • 相关文献

参考文献6

二级参考文献36

  • 1李家泰,王彤,贾延军,李曼宁.临床分离耐药菌中超广谱β-内酰胺酶特性研究[J].中国临床药理学杂志,1996,12(2):81-84. 被引量:15
  • 2朱世俊.现代医院感染学(第1版)[M].北京:人民军医出版社,1998.20.
  • 3[1]Bou G, Oliver A, Martrinez J, et al. OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain[J]. Antimicrob Agents Chemother, 2000, 44(6): 1556-1561.
  • 4[2]Iregbu K C, Ogunsola F T, Odugbemi T O. Infections caused by Acinetobacter species and their susceptibility to 14 antibiotics in Lagos University Teaching Hospital, Lagos[J]. West Afr J med, 2002, 21(3): 226-229.
  • 5[3]Scerpella E G, Wanger A R, Armitige L, et al. Nosocomial outbreak caused by 9 multiresistance clone of Acinetobacter baumannii; results of the case control and molecular epidemiologic investigations[J]. Infect Control Hosp Epidemiol, 1995, 16(2): 92-97.
  • 6[5]Fernandez-Cuenca F, Martinez-Martinez L, Conejo MC, et al. Relationship between beta-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii[J]. J Antimicrob Chemother, 2003, 51(3): 565-74.
  • 7[6]Gales A C, Tognim M C, Reis A O, et al. Emergence of an IMP-like metallo-enzyme in an Acinetobacter baumannii clinical strain from a Brazilian teaching hospital[J]. Diagn Microbiol Infect Dis, 2003, 45(1): 77-79.
  • 8[8]Rodriguez-Bano J, Pascual A, Gavez J, et al. Acinetobacter baumannii bacteremia: clinical and prognostic features[J]. Enferm Infect Microbiol Clin, 2003, 21(5): 242-277.
  • 9Cisneros JM, Reyes MJ, Pachon J, et al.Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features[J].Clin Infect Dis, 1996, 22(6): 1026-1032.
  • 10Rodriguez BJ, Pascual A, Galvez J, et al.Acinetobacter baumannii bacteremia: clinical and prognostic features[J].Enferm Infect Microbiol Clin, 2003, 21(5): 242-247.

共引文献353

同被引文献46

引证文献8

二级引证文献122

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部